?

        當前位置:標準品 > 標準物質 >
        脊髓灰質炎病毒1型(Sabin)的MAPREC分析100%480-A,525-C DNA(1st國際參考制
        ??【編號】:NIBSC00/410

        ??【名稱】:脊髓灰質炎病毒1型(Sabin)的MAPREC分析100%480-A,525-C DNA(1st國際參考制

        ??【規格】:個

        ??【價格】:2600元

          脊髓灰質炎病毒1型(Sabin)的MAPREC分析100%480-A,525-C DNA(1st國際參考制劑)

          編號:NIBSC00/410
          英文:MAPREC assay of poliovirus type 1 (Sabin).100% 480-A, 525-C DNA(1st International Reference Preparation)
          標準類型:國際參考制劑
          規格:1個 
        Customer Notes 00/416 - MAPREC assay of poliovirus type 1 (Sabin) Low Mutant Virus Reference(1st International Reference Preparation) 00/418 - MAPREC assay of poliovirus type 1 (Sabin) (1st International Standard) 00/422 - MAPREC assay of poliovirus type 1 High(Sabin) Mutant Virus Reference(1st International Reference Preparation)
          描述:1. INTENDED USE
        This control DNA for the MAPREC assay of polio virus type 1 (Sabin) is
        intended to be used as a validation sample for the assay. It is used to
        control the performance of the restriction enzymes. Dde I and Nci I, for
        example should digest this sample completely but assay conditions may
        reduce the efficiency of digestion. Conditions of restriction enzyme
        digestion should be optimized with this sample and monitored for
        consistency thereafter.
        2. CAUTION
        This preparation is not for administration to humans or animals in
        the human food chain.
        The material is not of human or bovine origin.
         As with all materials of biological origin, this preparation should be
        regarded as potentially hazardous to health. It should be used and
        discarded according to your own laboratory's safety procedures. Such
        safety procedures should include the wearing of protective gloves and
        avoiding the generation of aerosols. Care should be exercised in
        opening ampoules or vials, to avoid cuts.
        3. UNITAGE
        Preparation 00/410 is assigned a nominal value of 100% 480-A, 100%
        525-C.
        4. CONTENTS
        Country of origin of biological material: USA.
        Each DIN 58-377 ampoule contains the freeze-dried residue of cloned
        DNA that spans nucleotides 445-561 of type 1 poliovirus (Sabin) RNA.
        The DNA was prepared at a nominal concentration of 0.01µg/ml in TE
        buffer pH7.5 (10mM Tris-HCl and 1mM EDTA) and 0.1% w/v lactose was
        added as a bulking agent prior to freeze-drying.
        5. STORAGE
        Unopened ampoules should be stored at -20°C or below.
        Rehydrate preparation 00/410 in 0.1ml of distilled water. Aliquot the
        rehydrated material in 10µl volumes and store at -70°C.
        Please note: because of the inherent stability of lyophilized
        material, NIBSC may ship these materials at ambient temperature.
        6. DIRECTIONS FOR OPENING
        DIN ampoules have an 'easy-open' coloured stress point, where the
        narrow ampoule stem joins the wider ampoule body. Various types of
        ampoule breaker are available commercially. To open the ampoule,
        tap the ampoule gently to collect material at the bottom (labelled) end
        and follow manufactures instructions provided with the ampoule
        breaker.
        7. USE OF MATERIAL
        No attempt should be made to weigh out any portion of the freeze-dried
        material prior to reconstitution
        A Standard Operating Procedure for the MAPREC assay is available
        from; Chief, Biologicals, World Health Organization. This procedure
        requires that an aliquot of 00/410 is tested in each MAPREC assay and
        used to validate the test.
        8. STABILITY
        Reference materials are held at NIBSC within assured, temperaturecontrolled
        storage facilities. Reference Materials should be stored on
        receipt as indicated on the label.
        NIBSC follows the policy of WHO with respect to its reference materials.
        9. REFERENCES
        1. WHO (2002) WHO Technical Report Series, 904, 31-91.
        2. European Pharmacopoeia, 6th Edition (2009) Vaccines for human use,
        Poliomyelitis vaccine oral 04/2008:0215.
        3. WHO /BS/09.2103. WHO Technical Report Series.
        10. ACKNOWLEDGEMENTS
        We thank the participants of the WHO collaborative study to evaluate the
        Poliovirus type1 MAPREC assay
          聲明:此對照品、標準品由【中檢計量】提供網站查詢購買服務
          注:點擊cas,或者搜索:名稱、編號、cas均可顯示價格
        上一篇:白介素3(小鼠,rDNA衍生) 下一篇:沒有了



          ?
          首 頁 | 對照品| 標準品| 標準物質| 實驗試劑| 培養基| 菌種購買| 新聞中心| 聯系我們| 網站地圖

          2011-2018 中檢計量-萊耀生物@版權所有

          ? 主站蜘蛛池模板: 宣恩县| 土默特右旗| 福建省| 黄骅市| 台北县| 扎鲁特旗| 桦南县| 乌兰县| 邵东县| 侯马市| 长海县| 昌宁县| 棋牌| 格尔木市| 云安县| 漳平市| 云安县| 遵化市| 枣阳市| 松潘县| 元阳县| 勐海县| 和田县| 乐山市| 宝鸡市| 东乡族自治县| 保德县| 乌兰察布市| 缙云县| 延长县| 宜黄县| 文昌市| 开化县| 阳山县| 旬邑县| 阿拉善右旗| 中方县| 德格县| 五河县| 迁安市| 卓尼县|